Follow the CSJ LinkedIn page. Search Clinical Services Journal
Campaign to protect workers from exposure to hazardous medicines
The Safer Healthcare and Biosafety Network (SHBN) has launched a new campaign titled “Protecting Healthcare Workers: Safer Handling of Hazardous Medicinal Products” to raise awareness of the dangers of occupational exposure to hazardous medicinal products (HMPs), the first of its kind in the UK. The launch follows oral questions raised in the
House of Commons by Luke Akehurst MP on 9 March (view at:
https://tinyurl.com/pwzk7kn8), who asked the Secretary of State for Work and Pensions what steps he is taking to improve the protection of workers against exposure to potentially hazardous medicinal products. This marks the first time HMPs and the risks they pose to workers have been formally raised in the House of Commons. Luke Akehurst MP then also asked if he will “consider developing a clear statutory definition of hazardous medicinal products and subsequently mandate the development, publication and ongoing maintenance of a comprehensive UK list of hazardous medicinal products?” HMPs are widely used across healthcare,
most notably in cancer treatment, but also in the management of conditions such as multiple sclerosis, HIV, psoriasis, and organ transplantation. These medicines include cytotoxic agents, antivirals, monoclonal antibodies, immunosuppressants, hormones, and certain antibiotics. While lifesaving for patients, many HMPs pose recognised health risks to the healthcare professionals who handle them due to unintentional exposure, including nurses, pharmacists and a large range of ancillary staff involved in their preparation, administration and disposal. HMPs are classified as carcinogenic, mutagenic
or reprotoxic (CMR) substances and long-term occupational exposure has been associated with symptoms like headaches, nausea, and respiratory issues, and even more severe health effects like infertility, miscarriage and increased cancer risk.
products handling standards to ensure all staff who may be exposed are properly trained and adequately protected. The routine use of closed- system handling, including the use of closed- system-transfer-devices (CSTDs) and systematic exposure monitoring should not be optional. The UK must align with international best practice and ensure that healthcare workers receive the same level of protection as their counterparts in Europe and the United States.” Louise Church, Royal College of Nursing (RCN)
Luke Akehurst, Labour MP for North Durham,
said: “The launch of Safer Healthcare Biosafety Network’s HMP Safety campaign, the UK’s first dedicated campaign focused on preventing occupational exposure to HMPs for all healthcare workers, is an important first step in the right direction. For too long, an invisible injustice has been happening to nurses in my constituency and across the country. The risk of exposure to HMPs is detrimental to the lives of those who care for us, and we must ensure that when NHS healthcare workers and private practitioners care for patients, they are not putting their own health on the line.” Dr. Paul Grime, Chairman of the Safer Healthcare Biosafety Network (SHBN), added: “The UK is long overdue a coherent national framework for the safe handling of hazardous medicinal products (HMPs). We are proud to launch the UK’s first dedicated campaign focused on protecting healthcare staff from the risks of occupational exposure to HMPs. It is hugely concerning that medicines designed to save patients’ lives can, through insufficient systems and inconsistent safeguards, cause avoidable harm to the professionals who handle them every day. “Our goal is to ensure there is clear national legislation that defines hazardous medicinal
Health, Safety and Wellbeing Senior National Officer, commented: “Nursing staff cannot continue to be put at potential risk of hazardous medicinal products (HMPs) exposure while clear definitions and guidance are so lacking. Immediate action is needed, with the UK falling behind EU countries and the US in providing comprehensive guidance and
protections...The UK Government, Health and Safety Executive, and employers themselves must take strong preventative action and back this campaign’s call to establish clear national standards aligned with international best practice.” The UK currently has no formal definition of
hazardous medicinal products, no nationally recognised list of such medicines, and no standardised, mandatory training or guidance for staff on how to handle them. The SHBN’s HMP Safety Campaign calls for legislative reform to establish clear national standards aligned with international best practice. Key priorities include: l Adoption of a statutory definition and national list of hazardous medicinal products.
l Mandating the use of closed system drug transfer devices and other engineering controls wherever exposure risk exists.
l Routine environmental monitoring and exposure registers.
l Reform of the current “as low as reasonably practicable” (ALARP) standard under COSHH to require exposure to be reduced to the lowest possible level.
Partnership will help advance understanding of implant failures
A new research partnership, led by Birmingham Health Partners members, the University of Birmingham and the Royal Orthopaedic Hospital NHS Foundation Trust (ROH), will help to improve understanding of the performance and failure of implants used in orthopaedic surgery. The Birmingham Implant Retrievals Centre will analyse orthopaedic implants that have failed and associated tissue samples. Researchers will use
these to analyse why devices fail, how implants behave inside the body, and how patient safety can be improved through earlier identification of risk. University of Birmingham researchers are applying advanced engineering expertise to the study of implants that have been retrieved from patients following revision joint replacements, working closely with surgeons at ROH to understand how devices perform over time in
patients. The Birmingham Implant Retrievals Centre hopes the work will enhance patient safety by earlier detection of risk failure, improve understanding of the causes of revision joint replacements, and develop evidence to support better screening and testing of implant devices. the findings will also feed into early warning systems and support compliance with guidance from organisations such as NICE, MHRA, FDA, and ODEP.
April 2026 I
www.clinicalservicesjournal.com 11
News
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
